Lataa...
Ipilimumab in patients with melanoma and autoimmune disease
Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4), an immune-checkpoint receptor and regulator of T-cell activation, has become an important therapeutic target for immunotherapy in cancer and autoimmune diseases. To date, clinical trials involving cancer immunotherapies, such checkpoint blocking antibodies...
Tallennettuna:
| Päätekijät: | , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2014
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4207313/ https://ncbi.nlm.nih.gov/pubmed/25349698 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-014-0035-z |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|